Protein Yıkımının Önemi

1. Doherty FJ. ve Mayer RJ. Intracellular protein degradation. IRL
Press, Oxford; 1992.
2. Schimke RT. Protein degradation in vivo and its regulation.
Circ Res 1976; 38, I131-7. Protein Yıkımının Önemi
99
3. Voet DD. ve Voet JG. Biochemistry. John Wiley & Sons, Inc.,
New York; 1995.
4. Yerlikaya A. ve Stanley BA. S-adenosylmethionine
decarboxylase degradation by the 26 S proteasome is
accelerated by substrate-mediated transamination. J Biol Chem
2004; 279, 12469-78.
5. Yerlikaya A. Cellular functions of the 26S proteasome. Turk J
Biol 2004; 28, 31-38.
6. Varshavsky A. The N-end rule: functions, mysteries, uses. Proc
Natl Acad Sci U S A 1996; 93, 12142-9.
7. Rechsteiner M. ve Rogers SW. PEST sequences and regulation
by proteolysis. Trends Biochem Sci 1996; 21, 267-71.
8. Rogers SW. ve Rechsteiner MC. Microinjection studies on
selective protein degradation: relationships between stability,
structure, and location. Biomed Biochim Acta, 1986; 45, 1611-
8.
9. Yerlikaya A. Protein sentezi ve yıkımı. In Yıldırım, A., Bardakçı, F., Karataş, M. ve Tanyolaç, B. (eds.), Moleküler Biyoloji. Nobel Yayınevi, Ankara; 2007.
10. Alberts B, Bray D, Lewis J, Raff M, Roberts K. ve Watson JD.
Molecular Biology of The Cell. Garland Publishing, Inc., New
York; 1994.
11. Agarraberes FA, Terlecky SR. ve Dice JF. An intralysosomal
hsp70 is required for a selective pathway of lysosomal protein
degradation. J Cell Biol 1997; 137, 825-34.
12. Pillay CS, Elliott E. ve Dennison C. Endolysosomal proteolysis
and its regulation. Biochem J 2002; 363, 417-29.
13. Cohen GM. Caspases: the executioners of apoptosis. Biochem J
1997; 326, 1-16.
14. Nagata S. Apoptosis by death factor. Cell 1997; 88, 355-65.
15. Philchenkov A. Caspases: potential targets for regulating cell
death. J Cell Mol Med 2004; 8, 432-44.
16. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157,
1415-30.
17. Nicholson DW. Caspase structure, proteolytic substrates, and
function during apoptotic cell death. Cell Death Differ 1999; 6,
1028-42.
18. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A. ve
Nagata S. A caspase-activated DNase that degrades DNA
during apoptosis, and its inhibitor ICAD. Nature 1998; 391, 43-
50.
19. Hilt W. ve Wolf DH. Proteasomes: destruction as a programme.
Trends Biochem Sci 1996; 21, 96-102.
20. Hershko A. ve Ciechanover A. The ubiquitin system. Annu Rev
Biochem 1998; 67, 425-79
21. Jentsch S. The ubiquitin-conjugation system. Annu Rev Genet
1992; 26, 179-207.
22. Hershko A, Ciechanover A, Heller H, Haas AL. ve Rose IA.
Proposed role of ATP in protein breakdown: conjugation of
protein with multiple chains of the polypeptide of ATPdependent proteolysis. Proc Natl Acad Sci U S A 1980; 77,
1783-6.
23. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda
DK. ve Varshavsky A. A multiubiquitin chain is confined to
specific lysine in a targeted short-lived protein. Science 1989;
243, 1576-83.
24. Voges D, Zwickl P. ve Baumeister W. The 26S proteasome: a
molecular machine designed for controlled proteolysis. Annu
Rev Biochem 1999; 68, 1015-68.
25. Pagano M. Cell cycle regulation by the ubiquitin pathway.
Faseb J 1997; 11, 1067-75.
26. He H, Qi XM, Grossmann J. ve Distelhorst CW. c-Fos
degradation by the proteasome. An early, Bcl-2-regulated step
in apoptosis. J Biol Chem 1998; 273, 25015-9.
27. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K,
Tamura T, Tanaka K. ve Ichihara, A. Ornithine decarboxylase
is degraded by the 26S proteasome without ubiquitination.
Nature 1992; 360, 597-9.
28. Hershko A. Ubiquitin-mediated protein degradation. J Biol
Chem 1988; 263, 15237-40.
29. Burger AM. ve Seth AK. The ubiquitin-mediated protein
degradation pathway in cancer: therapeutic implications. Eur J
Cancer 2004; 40, 2217-29.
30. Adams J. The development of proteasome inhibitors as
anticancer drugs. Cancer Cell 2004; 5, 417-21.
31. Lopes UG., Erhardt, P., Yao, R. ve Cooper, G.M. p53-
dependent induction of apoptosis by proteasome inhibitors. J
Biol Chem 1997; 272, 12893-6.
32. Yerlikaya A. ve Erin N. Differential sensitivity of breast cancer
and melanoma cells to proteasome inhibitor Velcade. Int J Mol
Med 2008; 22, 817-23.
33. Kandioler D, Dekan G, End A, Pasching E, Buchmayer H,
Gnant M, Langmann F, Mannhalter C, Eckersberger F. ve
Wolner E. Molecular genetic differentiation between primary
lung cancers and lung metastases of other tumors. J Thorac
Cardiovasc Surg 1996; 111, 827-31.
34. el-Deiry WS. Regulation of p53 downstream genes. Semin
Cancer Biol 1998; 8, 345-57.
35. Drexler HC. Activation of the cell death program by inhibition
of proteasome function. Proc Natl Acad Sci U S A 1997; 94,
855-60.
36. Drexler HC, Risau W. ve Konerding MA. Inhibition of
proteasome function induces programmed cell death in
proliferating endothelial cells. Faseb J 2000; 14, 65-77.
37. Dutaud D, Aubry L, Henry L, Levieux D, Hendil KB, Kuehn L,
Bureau JP. ve Ouali A. Development and evaluation of a
sandwich ELISA for quantification of the 20S proteasome in
human plasma. J Immunol Methods 2002; 260, 183-93.
38. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott
PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C,
Daud A. ve Spriggs DR. A phase I trial of the novel proteasome
inhibitor PS341 in advanced solid tumor malignancies. Clin
Cancer Res 2002; 8, 2505-11.
39. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin
AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS,
Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R,
Lehman MJ, Novick SC, O'Connor OA. ve Soignet SL. Phase I
trial of the proteasome inhibitor PS-341 in patients with
refractory hematologic malignancies. J Clin Oncol 2002; 20,
4420-7.